Merck to Pay $625M Plus Royalties in BMS Lawsuit

Jan 24, 2017

Yahoo! Finance

Bristol-Myers Squibb and partner Ono Pharmaceutical Company, Ltd. announced that they have signed a global patent license agreement with Merck & Co. to settle all patent-infringement litigation related to Merck’s anti-PD-1 therapy Keytruda.

Bristol-Myers Squibb and Ono had alleged that Merck’s sale of Keytruda had infringed the companies’ patents relating to the use of PD-1 antibodies to treat cancer in the United States, Europe, Australia and Japan.

According to an article in Yahoo! Finance, Merck will make an initial payment of $625 million to Bristol-Myers Squibb and Ono. In addition, Merck will pay ongoing royalties of 6.5 percent on global sales of Keytruda from Jan 1, 2017, through Dec. 31, 2023, and 2.5 percent from Jan 1, 2024, through Dec 31, 2026.

Read the full story


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments